普乐可复在肝脏移植术后的免疫治疗与监测

Immunotherapeutic and monitoring of tacrolimus in recipients of liver transplantation

目的:观察肝脏移植术后应用普乐可复(FK506)免疫治疗的临床效果。方法:回顾性分析我院69例患者肝脏移植术后使用以FK506为基础的三联免疫治疗方案的临床资料,即FK506+霉酚酸酯(MMF)+皮质激素。结果:69例中发生急性排斥反应8例(11.6%),经调整药物剂量后逆转。FK506的副作用主要有精神及神经系统紊乱(20.3%)、高血压(11.6%)、血糖升高(20.3%)及肝肾功能异常(8.7%)等。结论:FK506是一种安全、强效的免疫抑制药物,用药剂量应根据药物谷值浓度及个体差异进行调整。

Objective：To observe the clinic therapeutic effects of tacrolimus （FK506） in the recipients who had undergone liver transplantation.Methods＇The clinical data of 69 recipients of allogeneic liver transplantation followed by tacrolimus based immunotherapeutic scheme were retrospectively analyzed in our hospital.After liver transplantation, all the recipients received the trilogy-drug immunosuppressive protocol, including tacrolimus （FK506） as the basic drug, mycophenolat-mofetil （MMF）, and prednisone. Results：Acute rejection occurred in 8 of 69 cases （11.6%）.After adjusting drug dose, acute rejection was reversed.The main side-effects of tacrolimus were spirit and nervous system confusion （20.3%）, hypertension（11.6%）, hyperglycemia（20.3%）, liver and renal dysfunction（8.7%）.Conclusion：Tacrolimus is a safe and potent immunosuppressive medicine, the dosage of FK506 should be adjusted according to trough level within the therapeutic window and individualized.